Novo tratamento para câncer de pâncreas metastático aumenta o tempo de vida dos pacientes ASCO 26

***** Access my channels: Website - www.draviviancoski.com.br Instagram - www.instagram.com/draviviancoski Facebook - www.facebook.com/draviviancoski In this "Coffee with Dr. Vivian" live stream, oncologist Dr. Vivian Coski shares important updates presented at the American Society of Clinical Oncology (ASCO 2026) Congress, focusing on advancements in pancreatic and breast cancer. Main topics covered: • Metastatic Pancreatic Cancer (3:09 - 14:42): • RAS Solute 302 Study: Presentation of a new oral medication, Daroxan Razib, which demonstrated the potential to double lifespan and reduce the risk of death by 60% in patients who have already undergone prior treatment. • Early Diagnosis: Launch of the Spot-Me blood test, aimed at the early detection of 10 tumors, including pancreatic cancer, in people with risk factors. • Importance of Genetic Testing: Emphasis on the need to investigate BRCA1 and BRCA2 mutations and other molecular alterations (such as RET and HER2) to guide targeted therapies. • Breast Cancer and Lifestyle (19:12 - 27:39): • Dedica Study: Impressive results showing that the combination of a Mediterranean diet, daily exercise (30-minute walk), and vitamin D supplementation can reduce the risk of breast cancer recurrence by up to 76%. • Exercise Prescription: The doctor reinforces the WHO recommendation: at least 150 minutes of aerobic activity per week and strength training three times a week. • Question and Answer Session (3:52 PM - 6:26 PM and 8:46 PM - 8:52 PM): • Answers to questions about treatments, including the use of injectable vitamin C and disease progression in patients using CDK4/6 inhibitors (such as Abemaciclib), highlighting that specific courses of action depend on individualized medical evaluation.